<DOC>
	<DOCNO>NCT00003114</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy lomustine , etoposide , cyclophosphamide , procarbazine treat patient stage IIB , stage III , stage IV AIDS-related Hodgkin 's disease .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With AIDS-Related Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate , response duration , survival patient receive lomustine/etoposide/cyclophosphamide/procarbazine ( CECP ) stage IIB-IV AIDS-related Hodgkin 's disease . - Assess feasibility toxic effect CECP patient population . OUTLINE : Patients receive oral lomustine day 1 , oral etoposide day 1-3 , oral cyclophosphamide procarbazine day 22-31 . Filgrastim ( granulocyte colony-stimulating factor ) give subcutaneously day 5-21 33-42 . The course repeat every 6 week . Patients complete partial response 1 course treatment receive two additional course , lomustine omit second course . Patients partial response stable disease receive radiation therapy and/or continue chemotherapy . Patients fail respond 1 course remove study . Patients follow every 3 month death . PROJECTED ACCRUAL : A minimum 16 evaluable patient accrue .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIBIV AIDSrelated Hodgkin 's disease Patients Hodgkin 's disease HIVrelated condition must positive ELISA HIV confirm Western Blot Measurable evaluable disease No cytologic radiologic evidence CNS involvement PATIENT CHARACTERISTICS : Age : Any age Performance status : ECOG 03 Life expectancy : At least 6 week Hematopoietic : WBC least 1,500/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin great 3.0 mg/dL Renal : Creatinine great 3.0 mg/dL Other : Active infection allow ( provide prognosis estimate least 6 week ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Hodgkin 's disease At least 4 week since chemotherapy Kaposi 's sarcoma Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy localize stage I II disease progress beyond initial radiation port allow Surgery : Not specify Other : Concurrent AZT therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>AIDS-related lymphoma</keyword>
	<keyword>HIV-associated Hodgkin lymphoma</keyword>
</DOC>